SCHEMBL29989291

SCHEMBL29989291

CN(C)CCCNc1nc(Cl)ncc1C1CC1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 8/20 0.43
IGF1R P08069 1/20 0.41
CDK2 P24941 1/20 0.39
MARK3 P27448 1/20 0.39
IKBKE Q14164 1/20 0.39
BRSK2 Q8IWQ3 1/20 0.39
AURKB Q96GD4 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39
POLB P06746 1/20 0.38
TOP2A P11388 1/20 0.37
BRD4 O60885 1/20 0.36
ATAD2 Q6PL18 1/20 0.36
STK17B O94768 1/20 0.36
STK17A Q9UEE5 1/20 0.36
FERMT2 Q96AC1 1/20 0.36
PDPK1 O15530 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22818568 0.84 TBK1 (0.44) TBK1CDK2MARK3IKBKEBRSK2
SCHEMBL22818569 0.83 TBK1 (0.42) TBK1CDK2MARK3IKBKEBRSK2
SCHEMBL22818570 0.83 TBK1 (0.42) TBK1CDK2MARK3IKBKEBRSK2
SCHEMBL3387171 0.82 STK17A (0.42) TBK1CDK2MARK3IKBKEBRSK2
SCHEMBL13460158 0.82 TBK1 (0.43) TBK1CDK2MARK3IKBKEBRSK2
SCHEMBL22818563 0.82 TBK1 (0.49) TBK1CDK2MARK3IKBKEBRSK2
Hydrochloric Acid SCHEMBL3387745 0.81 STK17A (0.42) TBK1CDK2MARK3IKBKEBRSK2
SCHEMBL3389412 0.80 STK17A (0.49) TBK1CDK2MARK3IKBKEBRSK2
SCHEMBL22664726 0.80 TBK1 (0.40) TBK1CDK2MARK3IKBKEBRSK2
SCHEMBL12330667 0.79 BRD4 (0.45) POLBTOP2ABRD4ATAD2STK17B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2024-06-27 US disclosed
EP-4320121-A2 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS ULK1/2 INHIBITORS AND THEIR USE THEREOF LifeArc (GB) 2024-02-14 EP disclosed
CN-117545751-A 2, 4-diaminopyrimidine derivatives as ULK1/2 inhibitors and their use 生命爱科 2024-02-09 CN disclosed
WO-2022214869-A2 ULK1/2 INHIBITORS AND THEIR USE THEREOF LIFEARC (GB) 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208934-A1 ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 TBK1 38/4885IGF1R 1004/4885CDK2 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.